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ABSTRACT 
     Acute Lymphoblastic Leukemia (ALL) is the most common type of leukemia in children. It represents about 
75% of all leukemia types in children less than 15 years old and peak incidence at (2-5) years old. The study was 
designed to evaluate the effect of chemotherapeutic regimens used for Iraqi children with ALL by assessing 
anthropometric parameters, oxidative state markers, and metabolic state. This prospective randomized clinical 
study was carried out on (30) newly diagnosed children with ALL (6 months – 8 years old) in Iraq. According to 
the FAB-classification, the patients grouped as L1 group (n=16) and L2 group (n=14). A healthy children (n=14) 
were involved and considered as a control group to compare their normal data with these of patients groups. The 
IGF-I, albumin, total serum protein, BMI, TAS, and LDH were determined at baseline, 1st, 2nd, and 3rd months of 
the treatment regimen. The results showed that the mean level of serum IGF-I in both patient groups was 
significantly lower than that of control children at baseline, and it is increased significantly after receiving 
treatment while no significance difference between patients of both groups. Serum albumin, total serum protein, 
and BMI showed no significant differences in both patient groups when compared with the control group at 
baseline and after receiving treatment, also, between patients of both groups. TAS showed a significant reduction 
at baseline and after receiving treatment of both patients’ groups when compared with the control children, and 
there was a significant difference between patients of both groups. For LDH, there was a significant elevation in 
the mean level at baseline for both patients’ groups when compared with the control children, while after 
receiving treatment a significant reduction noticed in both groups when compared with control children and no 
significance difference between patients of both groups. These results can give indication for the effect of 
chemotherapy on the growth and nutrition of ALL children through their effects on IGF-I, which has a direct 
effect on GH and the reduction in the levels of total proteins and albumin, which may affect BMI, while the 
reduction in TAS during chemotherapy treatment may result in disruption of cells metabolism which will affect 
the normal body homeostasis. 
Keywords: ALL, Growth, IGF-I, Chemotherapy. 
 
INTRODUCTION 
     Leukemia is a malignant hematopoietic disease characterized by an uncontrolled proliferation and block in 
the differentiation of hematopoietic cells [1]. These malignant cells can spread mostly to the lymph nodes, liver, 
spleen, and other tissues. Leukemia largely classified as acute or chronic (according to the type of affected cells 
and by the rate of cells growth) and of myeloid or lymphoid according to the type of cell that is multiplying 
abnormally [2].  Acute lymphoblastic leukemia (ALL) is a group of heterogeneous lymphoid disorders that result 
from a monoclonal proliferation and expansion of immature B or T lymphocyte progenitor in the bone marrow, 
blood, and other organs [3]. ALL is a most common type of leukemia in children [4] with a peak incidence of age 
between 2-5 years of age and cure rate for about more than 80% [5].  
     In most patients, the main cause of ALL is unknown [3], the possible risk factors are genetics, environmental 
and infectious [6]. ALL classified to L1, L2, and L3 according to FAB-classification or to B-cell and T-cell 
neoplasm according to WHO-classification [7, 8]. ALL can diagnose by laboratory and pathological tests such as 
blood test, bone marrow aspirate, lymph node biopsy, cytogenetic test, lumbar puncture, and Immunophenotype 
[9, 10]
. Treatment for ALL can include blood transfusion, chemotherapy, radiation therapy, steroids, intensive 
combined treatments (including bone marrow or stem cell transplants), and growth factors. The main treatment 
for children with ALL is a chemotherapy, which is usually divided into 3 phases (induction phase, consolidation 
or intensification phase, and maintenance phase) [11]. 
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      Under normal conditions, IGF is responsible for growth and development of children, and it continues to 
mediate autocrine and paracrine functions throughout adulthood. In the endocrine system, IGF-I serum 
concentration is directly associated with growth hormone (GH) concentration; growth hormone stimulates the 
synthesis of IGF-I in the liver, which in turn stimulates growth and development. The deficiency of IGF-I in 
humans results in short stature [12]. Over the past two decades, greater evidence had accumulated to show that the 
growth factors play a vital role in maintaining or supporting the progression of neoplastic growth. A numbers of 
epidemiological evidence showed that it might also be an important determinant of cancer incidence [13]. 
     Oxidative stress defined as an imbalance between the production of free radicals and reactive metabolites, 
called oxidants or reactive oxygen species (ROS) [14]. Oxidative stress is closely concerning to all aspects of 
cancer, from carcinogenesis to the tumor-bearing state, and from the treatment to the prevention. When such 
oxidative stress exceeds the capacity of the oxidation-reduction system of the body, this may lead to result gene 
mutations or intracellular signal transduction and transcription factors may be affected directly or via 
antioxidants, leading to carcinogenesis [15]. 
 
AIM OF STUDY 
    The study was designed to evaluate the effect of ALL – therapeutic regimen for Iraqi children patients by 
assessment of anthropometric parameters, growth, oxidative state markers, and metabolic state. 
 
PATIENTS AND METHODS 
    This prospective case-control clinical study was carried out by (30) children patients (18 male, and 12 female) 
newly diagnosed with ALL. Those children were with an age range of (6 months – 8 years), and BMI range of 
(12.5-19.2 kg/m2).  The mean of age was (4.32 years).  Those child patients were diagnosed and treated in Child 
Center Hospital/ Unit of oncology/ AL-Iskan/ Baghdad, Iraq. Patients were allocated into two subgroups 
according to FAB – classification to L1 group (n=16) which include children with ALL – L1 subtype and a mean 
of age (3.81±0.535 years), and L2 group (n=14) which include children with ALL – L2 subtype and a mean of 
age (4.89±0.515 years). A healthy children (n=14) (8 female, and 6 male) with mean of age (3.85±0.606 years) 
were involved and considered as a control group to compare their normal data with that of patients groups. 
    The blood samples were obtained and centrifuged to get the serum and then assayed. The BMI, IGF-I, 
albumin, total serum protein, TAS, and LDH were determined at baseline before receiving any chemotherapy 
and after 1st, 2nd, and 3rd month of treatment for both patient groups. 
 
Statistical analysis 
     All data were presented as Mean ± SEM (Standard error of mean). Data were analyzed by two ways analysis 
of variance with (ANOVA), and (t-test), and the level of significance was (p<0.05). 
 
RESULTS 
     The results of this clinical study showed that the mean level of serum IGF-I in both patient groups was 
significantly (P<0.05) lower than that of control children at baseline, and it is increased significantly (P<0.05) 
after receiving chemotherapeutic agents at induction and consolidation phases and no significance difference 
(P>0.05) between patients of both groups. For serum albumin, total serum protein, and BMI value, there were 
insignificant differences (P>0.05) in mean of these parameters in both patient groups when compared with those 
of control group at baseline and after receiving treatment at induction and consolidation phases and also, in 
comparison between patients of both groups, but, there was a slight reduction in the mean level of these 
parameters at baseline and after receiving treatment. The oxidative state marker (TAS) showed a significant 
reduction (P<0.05) in its mean level at baseline and after receiving treatment at induction and consolidation 
phases of both patient groups when compared with the control children. Also, there was a significant difference 
(P<0.05) when compared between patients of both groups. For LDH, there was a significant elevation (P<0.05) 
in its mean level at baseline for both patient groups when compared with the control children, while after 
receiving treatment at induction and consolidation phases, a significant reduction (P<0.05) noticed in both 
groups when compared with control children, and no significance difference (P>0.05) in comparison between 
patients of both groups. See tables and figures (1, 2, 3, 4, 5, and 6, respectively). 
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Table (1): Effect of chemotherapy protocols on BMI value in ALL patients at induction and consolidation 
phases 
BMI value (kg/m2) 
Groups Baseline 1st month 2nd month 3rd month 
Control 
(n=14) 
 
15.89 ± 0.5906 
  
 
 
 
L1 group 
 (n=16) 
 
15.29 ± 0.5324a 
 
15.11 ± 0.5259a 
 
15.00 ± 0.5874a 
 
14.88 ± 0.6443a 
L2 group 
 (n=14) 
 
15.72 ± 0.5341a 
 
15.64 ± 0.4739a 
 
15.41 ± 0.4570a 
 
15.26 ± 0.4583a 
Results are expressed as mean ± SEM                                                                                                       Result 
with identical superscript (a) within the same group considered no significant difference (P>0.05)   
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Figure (1): Effect of chemoyherapy protocols on BMI value in ALL 
patients at induction and consolidation phases
Control
L1 group
L2 group
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Table (2): Effect of chemotherapy protocols on IGF-I level in ALL patients at induction and consolidation 
phases 
 
Results are expressed as mean ± SEM                                                                                                                * 
Significant difference (P<0.05) compared with the control group at the baseline level.                      
 Result with non-identical superscript (a, b, c) within the same group considered significant difference (P<0.05)                                                                                                                            
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Figure (2): Effect of chemotherapy protocols on IGF-I level in ALL 
patients on induction and consolidation phases 
Control
L1 group
L2 group
IGF-I level (ng/ml) 
 
Groups 
 
 
Baseline 
 
1
st
 month 
 
2
nd
 month 
 
3
rd
 month 
Control 
(n=14) 
 
 
107.8 ± 8.285 
 
 
 
 
 
 
L1 group 
(n=16) 
 
 
57.40 ± 8.176 
a*
 
 
69.71 ± 7.771 
a
 
 
86.38 ± 8.974 
b
 
 
104.7 ± 10.17 
c
 
L2 group 
(n=14) 
 
 
48.84 ± 7.824 
a* 
 
 
66.37 ± 9.246 
a 
 
 
80.92 ± 7.679 
b 
 
 
92.41 ± 8.734 
c 
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Table (3): Effect of chemotherapy protocols on Albumin level in ALL patients at induction and 
consolidation phases 
Albumin level (g/dL) 
 
Groups 
 
 
Baseline 
 
1st month 
 
2nd month 
 
3rd month 
Control 
(n=14) 
 
 
4.740 ± 0.2032 
 
 
 
 
 
 
L1 group 
 (n=16) 
 
 
4.409 ± 0.1908a 
 
4.256 ± 0.1278a 
 
3.979 ± 0.1200a 
 
3.933 ± 0.1182b 
L2 group 
 (n=14) 
 
 
4.401 ± 0.1779a 
 
4.286 ± 0.1603a 
 
4.123 ± 0.1239a 
 
4.010 ± 0.1611a 
Results are expressed as mean ± SEM                                                                                                       Result 
with non-identical superscript (a, b) within the same group considered significant difference (P<0.05)                                                                                                                            
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Figure (3): Effect of chemotherapy protocols on albumin level in ALL 
patients at induction and consolidation phases.
Control
L1 group
L2 group
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Table (4): Effect of chemotherapy protocols on total serum protein level in ALL patients at induction and 
consolidation phases 
Total serum protein level (g/dL) 
 
Groups 
 
 
Baseline 
 
1st month 
 
2nd month 
 
3rd month 
Control 
(n=14) 
 
 
10.10 ± 0.1760 
 
 
 
 
 
 
L1 group 
 (n=16) 
 
 
9.864 ± 0.3575a 
 
9.616 ± 0.2488a 
 
9.232 ± 0.2374a 
 
8.731 ± 0.2805b 
L2 group 
 (n=14) 
 
 
9.981 ± 0.3900a 
 
9.514 ± 0.3847a 
 
9.292 ± 0.3661a 
 
9.132 ± 0.4282a 
Results are expressed as mean ± SEM                                                                                                             
Result with non-identical superscript (a, b) within the same group considered significant difference (P<0.05)                                                                                                                            
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Figure (4): Effect of chemoyherapy protocols on total serum protien level 
in ALL patients at induction and consolidation phases.
Control
L1 group
L2 group
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Table (5): Effect of chemotherapy protocols on TAS level in ALL patients at induction and consolidation 
phases 
TAS level (mmol/L) 
Groups 
 
Baseline 1st month 2nd month 3rd month 
Control 
(n=14) 
 
 
2.183 ± 0.06921 
 
 
 
 
 
 
L1 group 
 (n=16) 
 
 
1.519 ± 0.1289a* 
 
1.596 ± 0.09910a 
 
1.624 ± 0.1398 a 
 
1.603 ± 0.1377 a 
L2 group 
 (n=14) 
 
 
2.096 ± 0.1661a† 
 
1.745 ± 0.08289a† 
 
1.531 ± 0.09220b† 
 
1.419 ± 0.07564c† 
Results are expressed as mean ± SEM                                                                                                              * 
Significant difference (P<0.05) compared with the control group at the baseline level                        
Result with non-identical superscript (a, b, c) within the same group considered significant difference (P<0.05)                                                                                                           
† Significance difference (P<0.05) between two ALL patient groups                                                  
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Figure (5): Effect of chemotherapy protocols on TAS level in ALL 
patients at induction and consolidation phses.
Control
L1 group
L2 group
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Table (6): Effect of chemotherapy protocols on LDH level in ALL patients at induction and consolidation 
phases  
LDH level (IU/L) 
 
Groups 
 
 
Baseline 
 
1st month 
 
2nd month 
 
3rd month 
Control 
(n=14) 
 
 
374.3 ± 13.58 
 
 
 
 
 
 
L1 group 
 (n=16) 
 
 
500.3 ± 34.24a* 
 
459.3 ± 29.70a 
 
411.4 ± 27.32a 
 
347.6 ± 32.56b 
L2 group 
 (n=14) 
 
 
482.5 ± 18.94a* 
 
405.4 ± 27.88b 
 
370.6 ± 23.30c 
 
359.2 ± 24.38d 
Results are expressed as mean ± SEM                                                                                                              * 
Significant difference (P<0.05) compared with the control group at the baseline level                        
Result with non-identical superscript (a, b, c, d) within the same group considered significant difference 
(P<0.05)  
 
 
DISCUSSION 
    The BMI results were supported by many studies and inconsistent with others. The studies that consistent with 
the current study had shown that the BMI of children with ALL disease was significantly decreased due to the 
effect of several factors like catabolic state by the disease itself or chemotherapeutic agents, reduced energy 
intake, infections, poor nutrition , and cranial irradiation [16, 17], while the studies that inconsistent with current 
results study showed that the BMI was increased due to the effect of corticosteroids which increase food intake 
and fats in adipose tissue [18], but the increase after chemotherapy suspension, also observed by other researchers, 
indicating an effect of treatment on body composition or progression in nutrient intake and capacity when 
therapy is removed [19]. 
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Figure (6): Effect of chemotherapy protocols on LDH level in ALL 
patients at induction and consolidation phases.
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L1 group
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    The IGF-I results of the present clinical study showed that there was a significant reduction in the mean level 
of serum IGF-I at diagnosis of ALL in both patient groups (L1 and L2) compared with the control group. This 
significant reduction was supported by previous observation, which showed that there was a reduction in the 
level of serum IGF-I at diagnosis stage due to the disease itself, malnutrition, and other catabolic effects as 
trauma, sepsis, and organs failure, but this reduction may increase gradually after receiving chemotherapy 
protocols [20, 21]. The exact reason or mechanism for this decline in serum level of IGF-I was still unknown [22], 
but some studies suggest that the ALL children have an elevated IGFBP-2/IGF-I ratio at diagnosis and at 6 
months after treatment and these may lead to severely catabolic state which may alter the IGF signaling pathway 
which in turn cause diminish in the level of IGF-I inside the body through the alteration in (GH/IGF-I) axis [23, 
24]
. 
     Within L1 and L2 group patients, the present study results showed that there was no significant difference in 
the mean level of serum IGF-I after 1st month of treatment compared with baseline level, while after 2nd, and 3rd 
months of treatment there was significant elevation in the mean level of serum IGF-I compared with baseline 
level. The significant elevation in serum level of IGF-I supported by some studies which showed that there was 
an increase in the level of IGF-I after receiving chemotherapy protocol treatment when compared with IGF-I 
level at diagnosis stage, and these elevation appear after receiving chemotherapy but not reach normal level until 
6 months of treatment or more, but sometimes there was a catch-up period (mainly in maintenance phase), 
suggested that the intensive chemotherapy may involve directly in growth retardation [23], and there was other 
reports suggested that chemotherapy had a negative effect on growth [24, 25]. The mechanism of alteration in the 
(GH/IGF-I axis) in children with ALL was multifactorial. Children with malignancy were severely catabolic, as 
shown by an increase in protein breakdown and protein synthesis. In addition, malignant diseases lead to 
alterations in the IGF-I signaling pathway, and IGF-II and express high levels of IGFBP-2 messenger ribonucleic 
acid, and protein were secreted by leukemic T cell [25]. Finally, there were some studies suggest that cytotoxic 
drugs impair the synthesis and production of IGF-I by the liver and its action on the cartilage growth plate 
[26]
.While there was no significant difference in the mean level of serum IGF-I at baseline, and after 1st, 2nd and 
3rd months of treatment between L1 and L2 group patient. 
    The albumin showed no significant difference in it is mean levels in L1 and L2 group patients when compared 
with the control group at the baseline level. Also there were non-significant differences found in the mean levels 
of serum albumin after 1st and 2nd months of treatment when compared with baseline level and within L2 group 
patients after 1st, 2nd, and 3rd months of treatment when compared with baseline level. These results were 
inconsistent with many studies which had shown that there was a significant decrease in serum albumin level and 
this decrease either from an increased loss or depressed synthesis of albumin.  A reduction  in synthesis of   
albumin  mainly reflects  end-stage  liver  disease, intestinal  malabsorption  syndromes and  protein  calorie  
malnutrition. The continuous decrease  in  serum albumin  result  in  a  shift  of  fluids  from the  intravascular  to  
the  interstitial space,  resulting  in depletion of  intravascular volume and formation of  edema  [27, 28]. Few 
studies showed that there were no significant differences in the level of serum albumin, but sometimes there was 
a slight decrease due to the effect of chemotherapeutic agents especially L- asparaginase [29]. While within L1 
group, there was significant reduction in the mean level of serum albumin in 3rd month after treatment when 
compared with baseline level, and this result was consistent with many studies which had shown that there were 
significant reductions in serum albumin levels after chemotherapy regimen [27, 28].When compared between L1 
and L2 group patients, there were no significant differences in the mean levels of serum albumin at baseline, and 
after 1st, 2nd, and 3rd months of treatment. 
     The total serum protein showed that there was no significant difference in it is mean levels of total serum 
protein in L1 and L2 group patients when compared with the control group at the baseline level. Also within L1 
group patients, there were no significant differences in the mean levels of total serum protein after 1st and 2nd 
months of treatment when compared with baseline level, and within L2 group patients, there were no significant 
differences in the mean levels of total serum protein after 1st, 2nd, and 3rd months of treatment when compared 
with baseline level. These results were inconsistent with most studies which had shown that there were 
significant decreases in the levels of total protein due to the effect of ALL on patient groups when compared 
with healthy children [28, 30, 31]. These studies and others showed a significant reduction in total serum protein due 
to the effect of disease and low intake of protein [32]. To some extent, there were some studies consistent with the 
current study which showed that the level of total serum protein not affected or there were a slight decrease in its 
level due to the effect of corticosteroid which cause increase food intake and metabolism alteration [33]. While 
after 3rd months of treatment, for L1 group patients there was significant reduction in total serum protein mean 
level when compared with baseline level, this result was supported by many studies which had shown that there 
were significant reductions in the levels of total serum protein, and this reduction was due to malnutrition or 
acute loss of protein because of side effect of cancer therapy, reduced protein intake coupled with a 
hypermetabolic state, resulting in rapid depletion of visceral protein, and this indicate a catabolic protein status 
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[27, 34]
.When compared between L1 and L2 group patients, there were no significant differences in the mean 
levels of total serum protein at baseline, and after 1st, 2nd, and 3rd months of treatment.  
     For TAS the present clinical study showed a significant reduction in the mean level of serum TAS in L1 
group patients when compared with control group at baseline level, while there was no significant difference in 
the mean level of serum TAS in L2 group patients when compared with control group at baseline level. This 
result was proved accordingly by some studies which showed that the level of serum TAS lowered in patients 
with ALL than the healthy children [35] and this reduction may be due to an imbalance between oxidative and 
antioxidant status (the reduction of antioxidant status in plasma with ALL children was probably associated with 
increased ROS as indicated by the decrease in the antioxidant activity) [36, 37].Within L1 group patients, there was 
no significant difference in the mean level of serum TAS after 1st, 2nd, and 3rd months of treatment when 
compared with the baseline level. These results were inconsistency with most studies, but there were a certain 
study prove that, which its depending on the fact that the clearance of chemotherapeutic agents occur within 
hours or few days, and one of the reasons to decrease the level of TAS was the presence of chemotherapy inside 
the body [38]. Regarding L2 group, the present clinical study showed no significant difference in the mean level 
of serum TAS after 1st month of treatment compared with baseline level, while after 2nd and 3rd months of 
treatment there was significant reduction in the mean level of serum TAS when compared with baseline level. 
These results were supported by a lot of studies which report that during initiation or starting with chemotherapy 
treatment there was a decrease in the level of serum TAS due to affecting on dietary intake [39, 40]. Also, some 
studies showed that the cortisol can decrease the serum TAS level through inhibition of nuclear factor- κB [41]. 
Emotional and biological stressful condition may be contributed to increasing cortisone level which in turn leads 
to decrease in serum TAS level [42]. 
When compared between L1 and L2 group patients, the current study showed significant differences in the mean 
levels of serum TAS at baseline, and after 1st, 2nd, and 3rd months of treatment due to difference in intensity of 
chemotherapeutic regimen and sometimes there was simple difference due to difference in sex, age, dietary 
supplement, geographical location [43]. 
     The current clinical study had shown a significant elevation in the mean level of serum LDH in L1 and L2 
group patients when compared with the control group at the baseline level. This result was consistent with many 
studies which showed that, in ALL patients, there was marked elevation in serum concentration of LDH due to 
tissue damage and rapid cell turnover, this elevation in cellular LDH activity reflects a shift toward anaerobic 
metabolism and increased glycolysis in the cytoplasm of malignant cells accompanied by high cellular turnover 
rate (LDH involved in tumor initiation and metabolism) [44]. This increase in LDH concentration represents a 
prognostic marker for disease [45, 46]. Also, LDH considered a marker for oxidative state inside the human body, 
so the elevation of LDH concentration lead to increasing generation of ROS which in turn increase genesis of 
cancer and increase the cardiotoxicity especially with anthracycline and cyclophosphamide [47]. The mechanism 
for cardiotoxicity caused by anthracycline was through generation the ROS and leads to myocyte injury. Cardiac 
myocytes were highly susceptible to oxidative damage due to their intensive oxidative metabolism and relatively 
poor antioxidant defense [48, 49]. Within L1 group patients, there were no significant differences in the mean 
levels of serum LDH after 1st and 2nd months of treatment, while after 3rd months of treatment there was 
significant reduction in mean level of serum LDH when compared with baseline level. In L2 group patients, 
there were significant reductions in the mean levels of serum LDH after 1st, 2nd, and 3rd months of treatment 
when compared with the baseline level. The insignificant results during 1st and 2nd months in L1 group were 
supported by some studies which showed that some patients not responded to usual doses of chemotherapy 
because of the difference in individual biology of cancer cell or the malignant cells may acquire additional 
characteristics of invasiveness and reduce sensitivity due to increasing genetic instability that result from 
decreasing cell cycle control mechanism [50, 51]. Other results which had shown a decrease in LDH concentration 
were observed by many studies, where the concentration of LDH was dropped gradually until reach normal 
value because of lympholysis following chemotherapy regimen. The reduction in the level of LDH means that 
there is clinical and hematological remission [44, 50, 52]. When compared between L1 and L2 group patients, there 
were no significant difference in the mean level of serum LDH at baseline, and after 1st, 2nd and 3rd months of 
treatment.  
 
CONCLUSION 
     Chemotherapy affect the growth and nutritional status of ALL children through their effects on the pathway 
of IGF-I synthesis, which in turn had a direct effect on GH and also, reduction in the levels of total proteins and 
albumin, which in turn effect on BMI of patients. The antioxidant level decreased significantly during 
chemotherapy treatment and led to cells metabolism alteration due to increased oxidative damage and metastasis 
of the disease, and these might lead to long term complications like nutritional and metabolic dysfunctions. 
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